Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

211.97
+7.903.87%
Post-market: 211.970.00000.00%19:58 EDT
Volume:645.00K
Turnover:136.31M
Market Cap:11.10B
PE:-56.25
High:214.64
Open:202.95
Low:201.94
Close:204.07
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:0.92
T/O Rate:1.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:133.28
PE(LYR):-57.57

Loading ...

Axsome Therapeutics Q1 Pretax Profit USD -64.542 Million

THOMSON REUTERS
·
May 04

Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
May 04

Axsome Therapeutics price target raised to $270 from $250 at H.C. Wainwright

TIPRANKS
·
May 04

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 04

U.S. Earnings Preview: Before Market Open May 4

Dow Jones
·
May 04

U.S. RESEARCH ROUNDUP- Alphabet, Colgate-Palmolive, Welltower

Reuters
·
May 04

Axsome Therapeutics (AXSM) Is Up 11.1% After FDA Clears AUVELITY For Alzheimer’s Agitation Treatment

Simply Wall St.
·
May 04

Axsome Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
May 02

Axsome Therapeutics price target raised to $255 from $215 at TD Cowen

TIPRANKS
·
May 01

Axsome Therapeutics Inc : TD Cowen Raises Target Price to $255 From $215

THOMSON REUTERS
·
May 01

Axsome Therapeutics Hosts Auvelity® FDA Approval Investor Event Featuring Expert Thought Leader

THOMSON REUTERS
·
May 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01

U.S. RESEARCH ROUNDUP-Caterpillar, Textron, Wesco International

Reuters
·
May 01

Assessing Axsome Therapeutics (AXSM) Valuation After Recent Share Price Momentum

Simply Wall St.
·
May 01

Axsome Therapeutics price target raised to $217 from $207 at Morgan Stanley

TIPRANKS
·
May 01

Axsome Therapeutics given ‘clean label’ for Auvelity in ADA, says TD Cowen

TIPRANKS
·
May 01

US FDA approves Axsome's drug for Alzheimer's-related agitation

Reuters
·
May 01

Axsome Therapeutics Announces FDA Approval of Auvelity® (Dextromethorphan Hbr and Bupropion Hcl) for the Treatment of Agitation Associated With Dementia Due to Alzheimer’s Disease

THOMSON REUTERS
·
May 01

NASDAQ TRADE HALT HALT NEWS PENDING AT 02:03 PM

Reuters
·
May 01

Mizuho Securities Adjusts Axsome Therapeutics Price Target to $228 From $230, Maintains Outperform Rating

MT Newswires Live
·
Apr 28